Analysts’ Updated EPS Estimates for July, 14th (XELA, XLRN, XNCR, XPER, Y, YELP, YMAB, YORW, YTEN, YTRA)

Analysts’ updated eps estimates for Sunday, July 14th:

Exela Technologies (NASDAQ:XELA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $2.25 target price on the stock. According to Zacks, “Exela Technologies, Inc. is engaged in providing information and transaction processing solutions. The Company’s segments include Information and Transaction Processing Solutions, Healthcare Solutions and Legal & Loss Prevention Services. ITPS provides industry solutions for banking and financial services, including lending solutions for mortgages, banking solutions for clearing, anti-money laundering, sanctions, cross-border settlement; property and casualty insurance solutions for enrollments, and communications. The HS segment offerings include integrated accounts payable and accounts receivable, and information management for both the healthcare payer and provider markets. The LLPS segment solutions include processing of legal claims for class action and mass action settlement administrations, involving project management support, notification and collection, analysis, and distribution of settlement funds. Exela Technologies Inc., formerly known as Quinpario Acquisition Corp. 2, is based in United States. “

Acceleron Pharma (NASDAQ:XLRN) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. “

Xencor (NASDAQ:XNCR) was downgraded by analysts at Zacks Investment Research from a hold rating to a strong sell rating. According to Zacks, “Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. “

Xperi (NASDAQ:XPER) was downgraded by analysts at Zacks Investment Research from a strong-buy rating to a hold rating. According to Zacks, “Xperi Corp. is a product and technology licensing company which manufactures semiconductors and related products. Its technologies and intellectual property are deployed, in areas such as premium audio, computational imaging, computer vision, mobile computing and communications, memory, data storage, 3D semiconductor interconnect and packaging. Xperi Corporation, formerly known as Tessera Holding Corporation, is headquartered in San Jose, CA. “

Alleghany (NYSE:Y) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. They currently have $809.00 target price on the stock. According to Zacks, “Shares of Alleghany have outperformed the industry in a year’s time. The company's strong performance across insurance and reinsurance operations will continue to boost its premium revenues. Alleghany strives to grow via both acquisitions and organic means as these not only diversify and strengthen its portfolio but also expand its global footprint. A solid balance sheet with increase in liquidity and decrease in debt and modest leverage supports the company’s shareholder-friendly moves and its growth initiatives. Continued strong underwriting performances by TransRe and RSUI, CapSpecialty and PacificComp should drive the results in the near term. However, exposure to catastrophe losses induces volatility in underwriting results. Also, escalating expenses weighing on margin expansion also remain a concern for the company.”

Yelp (NYSE:YELP) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. The firm currently has $37.00 price target on the stock. According to Zacks, “Yelp is benefiting from strong growth in ad revenues. The company’s shift toward selling advertising plans without any fixed duration is leading to a robust increase in paying advertiser accounts. The collaboration with GrubHub is a tailwind for Yelp as it provides users with access to a significant number of restaurants available for food ordering on the platform. Besides, the company is witnessing acceleration in consumer traffic across app unique devices. Significant improvement in cumulative reviews is also encouraging. Shares have outperformed the industry in the past year. However, increase in operating expenses driven by an expected increase in headcount, product development and sales & marketing expenses will remain an overhang on the bottom line. Stringent competition from search giants like Google and Bing is a big threat.”

Y-mAbs Therapeutics (NASDAQ:YMAB) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company’s product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA. “

York Water (NASDAQ:YORW) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “The York Water Company impounds, purifies and distributes water. They are regulated by the Pennsylvania Public Utility Commission in the areas of billing, payment procedures, dispute processing, terminations, service territory, and rate setting. They must obtain PPUC approval before changing any of the aforementioned procedures. “

Yield10 Bioscience (NASDAQ:YTEN) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Yield10 Bioscience, Inc. is an agricultural bioscience company. It focuses on the development of disruptive technologies for improvement in crop yield to enhance global food security. The company is working on new approaches, to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism for better production. It operates primarily in Saskatoon, Saskatchewan, Canada. Yield10 Bioscience, Inc., formerly known as Metabolix, Inc., is based in Woburn, Massachusetts. “

Yatra Online (NASDAQ:YTRA) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Yatra Online, Inc. provides online travel agency services. The company operates through website www.yatra.com, mobile applications and associated platforms to book airline, railway and bus tickets as well as car and hotel accommodations for customers. Its product portfolio includes flights, hotels, trains, holidays, bus and activities. Yatra Online, Inc. is headquatered in New Delhi, India. “

Zendesk (NYSE:ZEN) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $103.00 price target on the stock. According to Zacks, “Zendesk, Inc. is a software development company. It provides a software-as-a-service, or SaaS, customer service platform. The Company offers applications that allow clients to manage incoming support requests from end customers from any Internet connected computer. It provides customer service through its platform in approximately 40 languages to customers in various industries, such as business technology, telecommunications, education/non-profit, consumer technology, media/entertainment, and retail/ecommerce. Zendesk, Inc. is headquartered in San Francisco, California. “

ZovioInc . (NYSE:ZVO) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Zovio Inc. is an education technology services company which partners with higher education institutions and employers to deliver innovative, personalized solutions to help learners and leaders achieve their aspirations. Zovio Inc., formerly known as Bridgepoint Education Inc., is based in San Diego, United States. “

Receive News & Ratings for Exela Technologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exela Technologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.